<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655902</url>
  </required_header>
  <id_info>
    <org_study_id>B237</org_study_id>
    <nct_id>NCT00655902</nct_id>
  </id_info>
  <brief_title>Copenhagen Obesity Risk Assessment Study</brief_title>
  <acronym>COBRA</acronym>
  <official_title>Copenhagen Obesity Risk Assessment Study - A Double Blind Randomized Dietary Intervention Study Examining the Effect of a High Intake of Trans Fatty Acids on Abdominal Obesity and Risk Markers of Type 2 Diabetes and Cardiovascular Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to assess the effect of a high intake of industrially
      produced trans fatty acids for 16 weeks on abdominal obesity and risk markers of type 2
      diabetes and heart disease in healthy, moderately overweight, postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in LDL-cholesterol/LDL-cholesterol ratio</measure>
    <time_frame>week 0, 8, 16 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Liver fat measured by MR-S</measure>
    <time_frame>week 0, 16 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Insulin sensitivity (ISI composite) from 3h OGTT</measure>
    <time_frame>week 0, 8, 16 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Waist circumference</measure>
    <time_frame>week 0, 8, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visceral adipose tissue measured by MR</measure>
    <time_frame>week 0, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intramuscular fat measured by MR-S (Psoas Major)</measure>
    <time_frame>week 0, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body fat percentage measured by DEXA</measure>
    <time_frame>week 0, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24h heart rate variability measured by Holter-monitoring</measure>
    <time_frame>week 0, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cytokines in blood</measure>
    <time_frame>week 0, 8, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cytokines in abdominal adipose tissue</measure>
    <time_frame>week 0, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Ceramide in abdominal adipose tissue</measure>
    <time_frame>week 0, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Metabolomic profile in blood and urine</measure>
    <time_frame>week 0, 16 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Abdominal Obesity</condition>
  <condition>Heart Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Trans fat (soy bean oil)</intervention_name>
    <description>Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control fat (sunflower oil)</intervention_name>
    <description>Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 45-70 years

          -  BMI 25-32

          -  Waist circumference &gt; 80 cm

          -  Postmenopausal for at least 1 year

        Exclusion Criteria:

          -  BP &gt; 160/100 mmHg

          -  Fasted blood glucose &gt; 7 mM

          -  Fasted LDL-cholesterol &gt; 6 mM

          -  Fasted triglycerides &gt; 3 mM

          -  Diabetes mellitus or other chronic diseases

          -  Current or previous cardiovascular disease

          -  Weight change &gt; 3 kg within last 2 months

          -  Use of anti-hypertensive drugs

          -  Use of statins/fibrates

          -  Use of fish oil supplements

          -  Smoking

          -  Hard physical activity &gt; 10 h/week
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Human Nutrition, University of Copenhagen</name>
      <address>
        <city>Frederiksberg</city>
        <state>Copenhagen</state>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Bendsen NT, Haugaard SB, Larsen TM, Chabanova E, Stender S, Astrup A. Effect of trans-fatty acid intake on insulin sensitivity and intramuscular lipids--a randomized trial in overweight postmenopausal women. Metabolism. 2011 Jul;60(7):906-13. doi: 10.1016/j.metabol.2011.01.009. Epub 2011 Mar 11.</citation>
    <PMID>21397284</PMID>
  </results_reference>
  <results_reference>
    <citation>Bendsen NT, Chabanova E, Thomsen HS, Larsen TM, Newman JW, Stender S, Dyerberg J, Haugaard SB, Astrup A. Effect of trans fatty acid intake on abdominal and liver fat deposition and blood lipids: a randomized trial in overweight postmenopausal women. Nutr Diabetes. 2011 Jan 31;1:e4. doi: 10.1038/nutd.2010.4.</citation>
    <PMID>23154296</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <last_update_submitted>April 28, 2011</last_update_submitted>
  <last_update_submitted_qc>April 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. med, prof. Arne Astrup</name_title>
    <organization>Department of Human Nutrition, University of Copenhagen</organization>
  </responsible_party>
  <keyword>Trans fat</keyword>
  <keyword>Obesity</keyword>
  <keyword>Insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

